Large-scale exome datasets reveal a new class of adaptor-related protein complex 2 sigma subunit (AP2 sigma) mutations, located at the interface with the AP2 alpha subunit, that impair calcium-sensing receptor signalling by Gorvin, Caroline M et al.
For Peer Review
 
 
 
 
 
 
Large-scale exome datasets reveal a new class of adaptor-
related protein complex 2 sigma subunit (AP2σ) mutations, 
located at the interface with the AP2 alpha subunit that 
impair calcium-sensing receptor signalling 
 
 
Journal: Human Molecular Genetics 
Manuscript ID HMG-2017-D-01039.R1 
Manuscript Type: 2 General Article - UK Office 
Date Submitted by the Author: 20-Dec-2017 
Complete List of Authors: Gorvin, Caroline; University of Oxford, Radcliffe Department of Medicine 
Metpally, Raghu; Geisinger Center, Geisinger Center 
Stokes, Victoria; University of Oxford, Radcliffe Department of Medicine 
Hannan, Fadil; University of Liverpool, Department of Musculoskeletal 
Biology; University of Oxford, Radcliffe Department of Medicine 
Krishnamurthy, Sarathbabu; Geisinger Center, Weis Center for Research 
Overton, John; Regeneron Pharmaceuticals Inc, Regeneron Genetics Center 
Reid, Jeffrey; Regeneron Pharmaceuticals Inc, Regeneron Genetics Center 
Breitwieser, Gerda; Geisinger Clinic, Weis Center for Research 
Thakker, Rajesh; University of Oxford, Radcliffe Department of Medicine 
Key Words: 
Calcium homeostasis, Clathrin-mediated endocytosis, G-proteins, G-protein 
coupled receptors 
  
 
 
Human Molecular Genetics
For Peer Review
 1 
Large-scale exome datasets reveal a new class of adaptor-related protein complex 2 sigma 
subunit (AP2σ) mutations, located at the interface with the AP2 alpha subunit, that 
impair calcium-sensing receptor signalling 
 
Caroline M. Gorvin1, Raghu Metpally2, Victoria J. Stokes1, Fadil M. Hannan1,3, Sarath B. 
Krishnamurthy2, John D. Overton4, Jeffrey G. Reid4, Gerda E. Breitwieser2, Rajesh V. 
Thakker1* 
 
1Academic Endocrine Unit, Radcliffe Department of Medicine, Oxford Centre for Diabetes, 
Endocrinology and Metabolism (OCDEM), University of Oxford, Oxford, UK 
2Geisinger Clinic, Weis Center for Research, Danville, PA 17822, USA 
3Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University 
of Liverpool, UK 
4Regeneron Genetics Center, Tarrytown, NY, USA 
 
Address correspondence and reprint requests to: Rajesh V. Thakker at the Academic Endocrine 
Unit, Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and 
Metabolism (OCDEM), Churchill Hospital, Oxford OX3 7LJ, United Kingdom. Tel no: 01865 
857501. Fax no: 01865 875502. Email: rajesh.thakker@ndm.ox.ac.uk 
 
  
Page 1 of 36 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 2 
ABSTRACT  
 
Mutations of the sigma subunit of the heterotetrameric adaptor-related protein complex 2 
(AP2σ) impair signalling of the calcium-sensing receptor (CaSR), and cause familial 
hypocalciuric hypercalcaemia type 3 (FHH3). To date, FHH3-associated AP2σ mutations have 
only been identified at one residue, Arg15. We hypothesized that additional rare AP2σ variants 
may also be associated with altered CaSR function and hypercalcaemia, and sought for these 
by analysing >111,995 exomes (>60,706 from ExAc and dbSNP, and 51,289 from the 
Geisinger Health System-Regeneron DiscovEHR dataset which also contains clinical data). 
This identified 11 individuals to have 9 non-synonymous AP2σ variants (Arg3His, Arg15His 
(x3), Ala44Thr, Phe52Tyr, Arg61His, Thr112Met, Met117Ile, Glu122Gly, Glu142Lys) with 3 
of the 4 individuals who had Arg15His and Met117Ile AP2σ variants having mild 
hypercalcaemia, thereby indicating a prevalence of FHH3-associated AP2σ mutations of ~7.8 
per 100,000 individuals. Structural modelling of the novel 8 AP2σ variants (Arg3His, 
sAla44Thr, Phe52Tyr, Arg61His, Thr112Met, Met117Ile, Glu122Gly and Glu142Lys) 
predicted that the Arg3His, Thr112Met, Glu122Gly and Glu142Lys AP2σ variants would 
disrupt polar contacts within the AP2σ subunit or affect the interface between the AP2σ and 
AP2α subunits. Functional analyses of all 8 AP2σ variants in CaSR-expressing cells 
demonstrated that the Thr112Met, Met117Ile and Glu142Lys variants, located in the AP2σ α4-
α5 helical region that forms an interface with AP2α, impaired CaSR-mediated intracellular 
calcium (Ca2+i) signalling, consistent with a loss-of-function, and this was rectified by 
treatment with the CaSR positive allosteric modulator cinacalcet. Thus, our studies 
demonstrate another potential class of FHH3-causing AP2σ mutations located at the AP2σ-
AP2α interface. 
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INTRODUCTION 
Familial hypocalciuric hypercalcaemia (FHH) is an autosomal dominant condition 
characterised by lifelong mild-to-moderate elevations of serum calcium concentrations in 
association with normal or mildly raised serum parathyroid hormone (PTH) concentrations and 
low urinary calcium excretion (1, 2). FHH is genetically heterogeneous and at present 
comprises three reported subtypes (FHH1-3). FHH1 (OMIM #145980) is due to heterozygous 
loss-of-function mutations affecting the G-protein coupled calcium-sensing receptor (CaSR), 
encoded by the CASR gene, and FHH2 (OMIM #145981) is due to heterozygous loss-of-
function mutations of the G-protein alpha-11 subunit (Gα11), encoded by the GNA11 gene (3, 
4). The CaSR and Gα11 play a critical role in systemic calcium homeostasis by detecting 
alterations in extracellular calcium (Ca2+e) concentrations and initiating multiple intracellular 
signalling cascades that include phospholipase-C-mediated accumulation of inositol 1,4,5-
trisphosphate (IP3), and increases in intracellular calcium (Ca
2+
i) concentrations (5, 6), which 
in turn leads to decreases in parathyroid hormone (PTH) secretion and increases in urinary 
calcium excretion (7).  
 
FHH3 (OMIM #600740) represents a clinically more severe form of FHH, which may be 
associated with symptomatic hypercalcaemia, osteoporosis, osteomalacia and cognitive 
dysfunction (8, 9). FHH3 is caused by mutations of the adaptor-related protein complex 2 
(AP2) sigma subunit (AP2σ), encoded by the AP2S1 gene which consists of 5 exons (Figure 
1). AP2, which is a ubiquitously expressed heterotetrameric protein comprising α, β, µ and σ 
subunits (10) (Supplementary Figure 1), plays a fundamental role in the clathrin-mediated 
endocytosis of G-protein coupled receptors (GPCRs) such as the CaSR. The AP2 complex 
operates as two heterodimers, one comprised of the AP2α and AP2σ subunits, and the other 
the AP2β and AP2µ subunits (11-13) (Supplementary Figure 1). In the inactive state, the AP2α 
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and AP2β subunits form a diamond-shaped outer complex, and the AP2µ and AP2σ subunits, 
are buried within the core of the AP2 complex (10-12, 14-16). Upon activation, AP2α and 
AP2β bend away from each other, with the AP2σ subunit accompanying AP2α and the AP2µ 
subunit being displaced towards the plasma membrane (11, 12, 14). In this open conformation, 
the AP2µ and AP2σ subunits bind to endocytic motifs on transmembrane cargo proteins, and 
thereby facilitate the association of clathrin with the AP2 complex (12, 14, 17).  
 
All 3 FHH3-associated mutations reported to date involve the AP2σ Arg15 residue (8, 18-22), 
which is located within the β2-strand (Figure 2), and each of the 3 different missense mutations 
(Arg15Cys, Arg15His or Arg15Leu) (Figure 1), are postulated to disrupt polar contacts 
between the AP2σ Arg15 residue and the dileucine motif within the intracellular domain of the 
CaSR, which likely targets it for endocytosis (8, 10, 18). Indeed, these 3 FHH3-associated 
AP2σ Arg15 mutations have been shown to alter CaSR cell-surface expression and to have a 
dominant-negative effect on CaSR-mediated signalling (8, 18). In contrast, other potential 
mutations of the AP2σ Arg15 residue (Arg15Gly, Arg15Pro or Arg15Ser) have not been 
observed in humans, and in vitro studies have shown these mutations to impair cell growth (8). 
These findings indicate that potential mutations affecting the AP2S1 gene, which is highly 
conserved in zebrafish, fruitfly, and yeast homolog proteins with >99%, >96% and >95% 
amino acid identity, respectively, may not be commonly observed as they affect cellular 
viability (13). Moreover, the large exome and genome datasets contain AP2S1 variants at very 
low frequencies. For example, examination of the >13,000 alleles from the exome variant 
server did not reveal the presence of any AP2σ variants, whilst the 1000Genomes and Exome 
Aggregation Consortium (ExAc) databases (23, 24) contained only 5 coding variants, and the 
dbSNP database had only one AP2σ missense variant.  The pathophysiological significance of 
these rare coding AP2σ variants is unknown, especially as these large sequencing projects do 
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not contain phenotype information on individuals. Thus, these rare coding AP2σ variants may 
be benign polymorphisms, and we have previously shown that some AP2σ variants do not alter 
CaSR signalling or result in an abnormal phenotype. For example, our in vitro examination of 
N-ethyl-N-nitrosourea (ENU) induced AP2σ variants in mice demonstrated that two missense 
AP2σ variants, Tyr20Asn and Ile123Asn, had no effect on CaSR signalling, and that mice 
heterozygous for a donor splice-site variant, which results in an in-frame deletion of 17 amino 
acids, had normal serum and urinary calcium, despite a >50% reduction in AP2σ protein 
expression (25). This emphasises the need for in vitro and in vivo functional assessments of 
AP2σ variants, in determining their potential role in the pathophysiology of calcium 
homeostasis.  
 
The DiscovEHR exome sequencing dataset, which has arisen from a collaboration between the 
Regeneron Genetics Center and Geisinger Health System (26), offers a new opportunity for 
studying the role of rare coding variants in human pathophysiology, as the dataset contains 
matched genotype and phenotype information from 51,289 individuals (26). We therefore 
investigated the DiscovEHR dataset, as well as the ExAc and dbSNP datasets, to identify rare 
coding AP2σ variants, and characterised their functional and clinical consequences. These 
studies demonstrated that AP2σ variants located at the interface between the AP2σ and AP2α 
subunits were associated with impaired CaSR signalling and hypercalcaemia. 
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RESULTS 
Identification of two AP2σ variants associated with hypercalcaemia in the DiscovEHR 
exome sequencing dataset 
An analysis of the DiscovEHR exome sequencing dataset, which at the time of investigation 
contained the exomes from 51,289 adult patients (26), revealed five females to have 
heterozygous coding AP2S1 variants (Supplementary Table 1, Figure 1). Three of these 
patients harboured the reported FHH3-causing Arg15His mutation located in exon 2 of AP2S1 
(Figure 1) (18), and two of these three patients were found to have mild hypercalcaemia (Table 
1). The other two patients had novel variants which comprised: a heterozygous G-to-A 
transition at nucleotide c.155, located in exon 3, leading to substitution of the wild-type (WT) 
phenylalanine (Phe) with the mutant tyrosine (Tyr) at residue 52 of the AP2σ protein; and a 
heterozygous G-to-T transversion at nucleotide c.350, located in exon 5, resulting in a missense 
substitution of the WT methionine (Met) to a mutant isoleucine (Ile) at residue 117 of the AP2σ 
protein (Figure 1, Supplementary Table 1). The novel Phe52Tyr and Met117Ile variants, which 
were observed only once in the DiscovEHR dataset and were absent in the ExAc dataset, 
affected evolutionarily conserved AP2σ residues (Figure 1), and assessments using the SIFT 
and Polyphen-2 prediction software (27, 28) revealed the following. SIFT predicted that both 
of these variants would be disease-causing or damaging, whilst Polyphen-2 predicted that 
Phe52Tyr would be tolerated, but that the Met117Ile was likely to be damaging 
(Supplementary Table 1). The Polyphen-2 predictions were found to be in agreement with the 
results of the serum calcium concentrations obtained from the Geisinger Health System 
electronic health records (Table 1), which revealed that the patient with the Phe52Tyr variant 
was normocalcaemic, but that the patient harbouring the Met117Ile AP2σ variant had mild 
hypercalcaemia (Table 1). Thus, these studies reveal that 4 out of 51,289 individuals in the 
DiscovEHR cohort harboured AP2σ variants that were associated with hypercalcaemia and/or 
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FHH3, thereby indicating an overall prevalence of ~7.8 per 100,000 for disease-causing AP2σ 
variants in this cohort. 
 
Identification of six non-synonymous AP2σ variants within the ExAc and dbSNP 
databases 
The identification of a non-Arg15 AP2σ variant that was associated with a mild elevation of 
serum calcium concentration (Figure 1 and Table 1) suggested that additional rare AP2σ 
variants that may disrupt calcium homeostasis may also be present in exome sequence 
databases. We therefore searched for AP2S1 variants in >60,706 unrelated individuals in the 
ExAc (24), 1000Genomes (23) and dbSNP datasets (Supplementary Tables 2 and 3). This 
identified twenty-seven AP2σ variants, which comprised 6 non-synonymous germline variants 
and 21 synonymous variants (Figure 1, Supplementary Tables 2 and 3). Variants involving the 
AP2σ Arg15 residue were not identified and there were also no nonsense mutations of AP2σ. 
This number of non-synonymous AP2σ variants was significantly lower than the expected 
numbers of missense (n=63.7) and nonsense (n=7.8) variants for a protein of 142 amino acids, 
estimated using the ExAc database (24), (observed AP2σ variants vs expected gene variants: 
missense = 0.009% vs 0.1%; and nonsense = 0% vs 0.01%, χ2=p<0.0001). Two of the non-
synonymous AP2σ variants were found in exon 2, and consisted of Arg3His (G>A at c.8) and 
Ala44Thr (C>T at c.130), one non-synonymous AP2σ variant Arg61His (C>T at c.182) was 
found in exon 3, and the remaining three non-synonymous variants were identified in exon 5, 
and consisted of Thr112Met (C>T at c.335), Glu122Gly (A>G at c.365), and Glu142Lys (G>A 
at c.424). All of these six non-synonymous variants, which were observed only once in the 
ExAc or dbSNP datasets and were not present in the DiscovEHR dataset, affected 
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evolutionarily conserved residues (Figure 1B-C), thereby, indicating they may represent 
pathogenic mutations rather than benign polymorphisms.  
 
Structural Characterisation of eight novel AP2σ variants  
The predicted effects of the eight novel non-synonymous AP2σ variants, which comprised two 
from the DiscovEHR dataset (Phe52Tyr and Met117Ile), five from the ExAc dataset (Arg3His, 
Arg61His, Thr112Met, Glu122Gly and Glu142Lys), and one from dbSNP (Ala44Thr), on the 
structure of the AP2σ protein and their interactions with other subunits within the AP2 complex 
were characterised (Figure 2). The eight AP2σ variants were found not to alter the secondary 
structure of the AP2σ α-helical or β-strand structures. Three-dimensional modelling of the 
AP2σ variants was undertaken using the reported crystal structure of the AP2 heterotetramer 
(12). The AP2σ subunit is comprised of five α-helices and a cluster of five β-strands (12), and 
the analysis of three-dimensional modelling, revealed that 4 of the variants were situated in the 
β-strand cluster, which is involved in the binding of the AP2σ subunit to the cargo protein 
dileucine motif (10) (Figure 2), and the other 4 variants were located in the α4 and α5 helices, 
which lie close to the AP2α subunit, that forms a heterodimer with AP2σ (11, 12) (Figure 3 
and Supplementary Figure 1). Further analysis of the 4 variants (Arg3His, Ala44Thr, Phe52Tyr 
and Arg61His) within the β-strand cluster, revealed that the Arg3His variant, which is located 
distal to Arg15 in the β1-strand (Figure 2B), would likely disrupt a polar contact between the 
WT Arg3 residue and the Asp72 residue on the β5-α2 loop (Figure 2C), and this would 
potentially impair stability of the AP2σ subunit. However, the Ala44Thr and Phe52Tyr 
variants, which are located in the α1-β3 loop and the β3-strand of the AP2σ subunit, 
respectively, were not predicted to disrupt intra- or inter-subunit interactions (Figure 2D-E), 
but the Arg61His variant, which is located in the β4-strand and close to the site of the dileucine 
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binding motif of membrane cargo proteins, was predicted to potentially disrupt the binding of 
AP2σ to membrane cargo proteins (Figure 2F-G). 
Similar analysis of the 4 variants (Thr112Met, Met117Ile, Glu122Gly and Glu142Lys) located 
in the α4-α5 region at the C-terminus of the AP2σ protein (Figure 2), revealed that the 
Thr112Met, Glu122Gly and Glu142Lys variants, would likely disrupt AP2σ-AP2α inter-
subunit interactions, and thereby impair the structural integrity of this heterodimer and/or 
activation of the AP2 complex (Figure 3A-F). However, the side chain of Met117 and the 
variant Ile117 face away from the AP2σ-AP2α interface, and thus the Met117Ile variant was 
not predicted to alter interactions with the AP2α subunit, or to disrupt contacts within the AP2σ 
α4-helix (Figure 3G-H). The consequences of all these predicted structural alterations resulting 
from the AP2σ variants, on CaSR-mediated signalling were further assessed (Figure 4 and 
Supplementary Figures 2 and 3). 
 
Effects of the eight novel AP2σ variants on CaSR-mediated signalling and treatment 
with cinacalcet 
To determine the effects of the AP2σ variants on CaSR-mediated signalling, HEK293 cells 
stably expressing the CaSR (HEK-CaSR) were transiently transfected with pBI-CMV4-AP2S1 
constructs expressing either the WT or mutant AP2σ proteins, as described (8). This 
bidirectional pBI-CMV4 vector allowed for co-expression of AP2σ and red fluorescent protein 
(RFP) at equivalent levels, as previously reported (8). The expression of AP2σ and RFP was 
confirmed by fluorescence microscopy and/or Western blot analyses (Supplementary Figure 
2A-B). The expression of AP2σ was shown to be similar in cells transiently transfected with 
WT or variant proteins and higher than the endogenous expression of AP2σ (Supplementary 
Figure 2B). The Ca2+e-induced Ca
2+
i responses of HEK-CaSR cells transiently expressing the 
Page 9 of 36 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 10 
AP2σ variants was assessed using a flow cytometry-based assay, as described (18). The 
reported FHH3-causing Arg15His AP2σ variant (18) was used as a loss-of-function control in 
the flow cytometry assays. The Ca2+i responses in WT and variant AP2σ-expressing cells 
increased in a dose-dependent manner following exposure to increasing concentrations of 
Ca2+e. However, responses in cells expressing the Thr112Met, Met117Ile or Glu142Lys AP2σ 
variants, which are all located in the α4-α5 helical region of the AP2σ subunit (Figure 3), were 
significantly reduced when compared to WT expressing cells (Figure 4A-C), consistent with 
these AP2σ variants leading to loss of CaSR function (18). Thus, the Thr112Met, Met117Ile 
and Glu142Lys variants and Arg15His mutant expressing cells showed a rightward shift in the 
concentration-response curves (Figure 4A-C), with significantly increased half-maximal 
(EC50) values (n = 4-8) of 3.39 mM (95% confidence interval (CI) 3.26-3.53 mM) for 
Thr112Met expressing cells (p<0.001), 3.41 mM (95% CI 3.29-3.54 mM) for Met117Ile 
expressing cells (p<0.001), 3.63 mM (95% CI 3.49-3.78 mM) for Glu142Lys expressing cells 
(p<0.0001), and 3.66 mM (95% CI 3.52-3.81 mM) for Arg15His expressing cells (p<0.0001), 
compared to 2.87 mM (95% CI 2.74-3.00 mM) for WT expressing cells (Figure 4D-F),  In 
contrast, cells expressing the other five AP2σ variants (Arg3His, Ala44Thr, Phe52Tyr, 
Arg61His, and Glu122Gly) had Ca2+i responses and EC50 values that were not significantly 
different to the WT expressing cells, indicating that they are likely to be benign polymorphisms 
and not mutations (Supplementary Figure 3). 
 
We have previously demonstrated that the elevated EC50 values for CaSR-mediated Ca
2+
i 
release in cells expressing the FHH3-causing AP2σ Arg15 mutations can be rectified by 
treatment with cinacalcet, which is a CaSR positive allosteric modulator (29). To investigate 
whether the loss-of-function observed in HEK-CaSR cells expressing the AP2σ Thr112Met, 
Met117Ile or Glu142Lys mutations may also be corrected by allosteric modulation, we tested 
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responses in the presence of 10 nM cinacalcet, a dose which normalises altered signalling 
responses of the FHH3-causing Arg15 AP2σ mutations (29). Treatment with 10nM cinacalcet, 
led to a leftward shift of the abnormal dose-response curves for all three variants (Figure 5A-
C), such that the EC50 values of AP2σ variant expressing cells were decreased and similar to 
values of WT AP2σ expressing cells (EC50 values without cinacalcet (n = 4-8) were 3.51 mM 
(95% CI 3.37-3.65 mM) for Thr112Met expressing cells (p<0.001), 3.41 mM (95% CI 3.29-
3.54 mM) for Met117Ile expressing cells (p<0.0001), and 3.55 mM (95% CI 3.40-3.70 mM) 
for Glu142Lys expressing cells (p<0.0001); with cinacalcet treatment, EC50 values (n = 4-8) 
were 3.01 mM (95% CI 2.87-3.16 mM) for Thr112Met expressing cells (p = not significant 
(ns)), 2.84 mM (95% CI 2.70-3.00 mM) for Met117Ile expressing cells (p = ns), and 3.04 mM 
(95% CI 2.94-3.14 mM) for Glu142Lys expressing cells (p = ns),compared to 2.98 mM (95% 
CI 2.87-3.10 mM) for WT expressing cells) (Figure 5D-F). Thus, cinacalcet is able to correct 
the loss-of-function associated with the AP2σ α4-α5 helix variants (Thr112Met, Met117Ile and 
Glu142Lys).  
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DISCUSSION 
Our studies, which have analysed exome datasets from ~112,000 individuals for AP2σ variants 
that may cause FHH3 and abnormalities of CaSR mediated signalling, provide several new 
insights about: the prevalence of FHH3-associated AP2σ mutations, the structural-functional 
consequences of these mutations; and the importance of the AP2σ α4 and α5 helices in 
mediating activation of the AP2 complex that has a critical role in clathrin-mediated 
endocytosis of cell-surface proteins such as GPCRs. Thus, our analysis of the DiscovEHR 
cohort, of adult patients from a stable regional population in Pennsylvania (30), has provided 
the first prevalence estimate for FHH3, and found this to be ~7.8 cases per 100,000, which is 
similar to the estimated prevalence of 1-9 cases per 100,000 for FHH1 (31), and in keeping 
with FHH being defined as a rare disease (32). Three out of the five DiscovEHR patients with 
rare AP2σ variants, had the Arg15His AP2σ mutation, which has been reported to cause a 
milder form of hypercalcaemia than the FHH3-causing Arg15Cys and Arg15Leu AP2σ 
mutations (8). In keeping with this, the Arg15His AP2σ mutation in the DiscovEHR cohort 
was associated with serum calcium concentrations that were mildly elevated, in 2 patients, or 
at the upper-limit-of-normal in one patient (Table 1). The two patients with the Arg15His 
mutation, who were hypercalcaemic, also had vitamin D deficiency and/or chronic kidney 
disease, and this may have influenced their mild hypercalcaemia (Table 1). In addition, our 
results reveal that some individuals who are heterozygous for the AP2σ Arg15His may be 
normocalcaemic and this is similar to the reports that heterozygous loss-of-function CaSR 
mutations, which are associated with hypercalcaemia in the majority of patients may also rarely 
be associated with normocalcaemia in some individuals (33, 34). Moreover, our results are the 
first to report that an AP2σ mutation (Met117Ile) that does not involve the Arg15 residue can 
impair CaSR-mediated signalling (Figure 4), and may be associated with hypercalcaemia 
(Table 1), consistent with FHH3. Thus, our findings indicate that non-Arg15 AP2σ mutations 
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may cause FHH3, and that the current practice of only searching for mutations of the AP2σ 
Arg15 residues in exon 2 will need to be altered to include DNA sequence analysis of the other 
AP2S1 exons. 
 
Indeed, our demonstration that mutations (e.g. Thr112Met, Met117Ile and Glu142Lys) located 
in the AP2σ α4-α5 helices impair the intracellular calcium signalling responses of CaSR-
expressing cells (Figure 4, Supplementary Table 4) indicate the importance of this region for 
CaSR signalling and/or clathrin-mediated endocytosis. Our structural studies predicted that 
variations in the AP2σ α4-α5 helices would disrupt contacts with the AP2α subunit, and thus 
are likely to impair AP2 complex formation and/or the conformational changes necessary for 
AP2 complex activation (Figure 3, Supplementary Table 4). Indeed, in previous studies in 
which AP2α was deleted in C.elegans, the AP2σ homolog was shown to be unstable, whilst 
the contacts between AP2β and AP2µ (which represents the other heterodimer in the AP2 
structure) were unaffected (13). Thus, these previous studies and our investigation of AP2σ α4-
α5 variants suggest that mutations located at the AP2σ-AP2α interface are likely to impair 
heterodimer function. These studies also indicate that AP2σ mutations could be divided into 
two types: those impairing cargo protein recognition, as is the case for Arg15 mutations; and 
those impairing AP2 complex activation, as is the case for AP2σ α4-α5 mutants. In addition, 
our in vitro investigations demonstrated that the CaSR positive allosteric modulator, cinacalcet, 
can normalise the impaired signalling responses associated with mutations (Thr112Met, 
Met117Ile and Glu142Lys) of the AP2σ α4-α5 helices, and this is similar to our previous report 
that cinacalcet can rectify the in vitro and in vivo abnormalities of CaSR-mediated signalling 
associated with AP2σ Arg15 mutants (29). Thus, cinacalcet may have therapeutic potential for 
patients who have such AP2σ mutations located in the α4-α5 helices, together with 
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symptomatic hypercalcaemia or additional clinical phenotypes such as cognitive dysfunction, 
that have been observed in patients with FHH3-causing Arg15 AP2σ mutations (8, 29).  
 
Our findings also highlight the importance of functional characterization of variants identified 
in large-scale sequencing databases (e.g. ExAc), to assess whether these may represent 
pathogenic mutations. Thus, population cohorts contain sequencing data on patients with a 
range of disorders (including diabetes mellitus type 2, heart disease and inflammatory bowel 
disease (24)), should be used with caution as representative of the ‘normal’ population. 
Furthermore, in the absence of clinical data, from the ExAc and dbSNP databases, it is difficult 
to determine whether the carriers within the cohort are unaffected by the disorder under 
investigation. However, the DiscovEHR cohort, which has available both genetic and clinical 
data (26), allows assessment of the pathogenic effect of genetic variants. In addition, our studies 
illustrate the reliability and difficulties associated with the pathogenicity prediction and three-
dimensional modelling programs (Supplementary Table 4). Thus, the pathogenicity and three-
dimensional modelling programs predicted that the AP2σ variants Thr112Met and Glu142Lys 
would likely be deleterious (Figure 3 and Supplementary Table 2) and that Ala44Thr would 
likely not be deleterious (Figure 2 and Supplementary Table 2), and this was found to be in 
agreement with the in vitro studies that assessed the effects of these variants on CaSR-mediated 
Ca2+i signalling (Figure 4 and Supplementary Figure 3). However, for other AP2σ variants such 
pathogenicity and three-dimensional modelling programs were not of value when used alone 
in correctly predicting the effect of the genetic variants. For example, two of the AP2σ variants, 
Arg61His and Glu122Gly, were predicted to be deleterious (Figures 2 and 3, Supplementary 
Table 2), but were instead found to have no effect on CaSR-mediated Ca2+i signalling 
(Supplementary Figure 3); while another, Met117Ile, which was predicted to be likely 
deleterious by pathogenicity programs (Supplementary Table 1) but not three-dimensional 
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modelling (Figure 3) had impaired signalling (Figure 4) and was associated with 
hypercalcaemia in the patient (Table 1). Finally, for the Arg3His and Phe52Tyr AP2σ variants, 
the pathogenicity and three-dimensional modelling programs gave different predictions (Figure 
2 and Supplementary Tables 1 and 2), and both of these were shown by in vitro studies to not 
result in impaired CaSR signalling (Supplementary Figure 3), and the Phe52Tyr variant to be 
associated with normocalcaemia in the patient (Table 1). Thus, it is important to investigate 
such genetic variants from large-scale sequencing databases with a range of different methods 
that include population data combined with clinical information, prediction programs, 
structural models, and in vitro functional studies, to establish variant pathogenicity.      
 
In conclusion, our studies have identified that non-Arg15 AP2σ mutations may be associated 
with impaired CaSR-mediated Ca2+i signalling and hypercalcaemia, and that such mutations 
may cluster at the AP2σ-AP2α inter-subunit interface, and disrupt formation of the AP2 
complex with deleterious effects on CaSR function and Ca2+e homeostasis.  
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MATERIALS AND METHODS 
Ethics Statement 
All clinical data and unique International Classification of Disease-9 (ICD9) codes for each 
patient were obtained from the electronic health records (EHR) in a de-identified manner 
through an approved data broker, in accordance with Institutional Review Board approvals (26, 
30).   
 
DiscovEHR patient cohort  
The study cohort has previously been described in detail (26). In brief, the cohort consisted of 
Geisinger Health System (GHS) patients within the MyCode Community Health Initiative (26), 
and whose germ-line DNA underwent whole exome sequencing. Participants were 59% 
females and 41% males, with a median age of 61 years, and predominantly White (98%) and 
were enrolled through primary care and specialty outpatient clinics. Exome sequencing was 
performed as previously described (26). Details of sample preparation, sequencing, sequence 
alignment, variant identification, genotype assignment and quality control steps, including the 
setting of allele balance at <0.7, high quality combined allele read depth (AD) of ≥8 reads, and 
per sample genotype quality (GQ) of ≥30, have been previously described (26) .   
 
Online exome and genome sequencing datasets 
Two online datasets (ExAc (http://exac.broadinstitute.org/) (24), which includes the 1000 
Genomes dataset (http://www.internationalgenome.org), and dbSNP 
(https://www.ncbi.nlm.nih.gov/projects/SNP/)) that contain population based sequencing 
information from >60,706 unrelated individuals were used.  
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Protein Sequence Alignment and Three-Dimensional Modeling of AP2σ Structure  
Protein sequences of AP2σ orthologs were aligned using ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) (35). SIFT (http://sift.jcvi.org/) and Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/) were used to predict the effect of amino acid 
substitutions (36, 37). AP2σ secondary structure was studied using Spider2 (38). AP2σ three-
dimensional modelling was undertaken using the reported AP2 structures (Protein Data Bank 
accession numbers 2XA7 and 2JKR) (10, 12). Molecular modelling was performed using the 
PyMOL Molecular Graphics System (Version1.2r3pre, Schrödinger, LL Pymol) (25). 
 
Cell culture, Constructs and Antibodi s 
Functional assessments of the AP2σ variants were performed using HEK293 cells stably 
expressing the full-length CaSR (HEK-CaSR), as previously described (3, 18). Cells were 
maintained in DMEM-Glutamax media (ThermoFisher) with 10% fetal bovine serum (Gibco) 
and 400µg/mL geneticin (ThermoFisher) at 37ºC, 5% CO2. Wild-type and mutant pBI-CMV4-
AP2S1 expression constructs were generated (using GenBank Accession Number: 
NM_021575.3), as described (8), and transiently transfected into HEK-CaSR cells using 
Lipofectamine 2000 (LifeTechnologies). The bidirectional pBI-CMV4 cloning vector was used 
as it facilitated the co-expression of AP2σ and RFP (8), and site-directed mutagenesis was used 
to generate the mutant AP2S1 constructs using the Quikchange Lightning Site-directed 
Mutagenesis kit (Agilent Technologies) and gene-specific primers (SigmaAldrich), as 
described (39). The presence of mutations was verified using dideoxynucleotide sequencing 
with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies) and an automated 
detection system (ABI3730 Automated capillary sequencer; Applied Biosystems) (39). 
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Successful transfection was confirmed by visualising RFP fluorescence using an Eclipse E400 
fluorescence microscope with a Y-FL Epifluorescence attachment and a triband 4,6-diamidino-
2-phenylindole-FITC-Rhodamine filter, and images captured using a DXM1200C digital 
camera and NIS Elements software (Nikon) (3, 8, 18). The expression of AP2σ was also 
determined by Western blot analysis using an anti-AP2σ antibody (Abcam) and expression of 
calnexin, used as a control, was determined by Western blot analysis using an anti-calnexin 
antibody (Millipore). The Western blots were visualized using an Immuno-Star WesternC kit 
(BioRad) on a BioRad Chemidoc XRS+ system (3).  
 
Intracellular Calcium Measurements 
The Ca2+i responses of HEK-CaSR cells expressing WT or mutant AP2σ proteins were assessed 
by a flow cytometry-based assay, as reported (3, 8, 18). In brief, HEK-CaSR cells were cultured 
in T75 flasks and transiently transfected 24 hours later with 8µg DNA (3). Forty-eight hours 
following transfection, the cells were detached, resuspended in calcium- and magnesium-free 
Hanks’ buffered saline solution (HBSS) and loaded with 1µg/mL Indo-1-acetoxymethylester 
(Indo-1-AM) for 1 hour at 37ºC. Transfected HEK-CaSR cells were incubated with either a 
20% aqueous solution of 2-hydroxypropyl-β-cyclodextrin (Sigma) (vehicle) or 10nM 
Cinacalcet-HCl (Cambridge Bioscience Ltd.), resuspended in vehicle and added to cells prior 
to flow cytometry analysis (29). After removal of free dye, cells were resuspended in Ca2+- and 
Mg2+-free HBSS and maintained at 37°C. Transfected cells, in suspension, were stimulated by 
sequentially adding Ca2+ to the Ca
2+- and Mg2+-free HBSS to increase the [Ca2+]e in a stepwise 
manner from 0-15 mM, and then analysed on a MoFlo modular flow cytometer (Beckman 
Coulter) by simultaneous measurements of RFP expression (at 525 nm), Ca2+i-bound Indo-1-
AM (at 410 nm), and free Indo-1-AM (i.e. not bound to Ca2+i) (at 485 nm), using a JDSU Xcyte 
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UV laser (Coherent Radiation), on each cell at each [Ca2+]e, as described (3, 18). The peak 
mean fluorescence ratio of the Ca2+i transient response after each individual stimulus was 
measured using Cytomation Summit software (Beckman Coulter), and expressed as a 
normalised response, as described (3, 18). Nonlinear regression of concentration-response 
curves was performed with GraphPad Prism using the normalised response at each [Ca2+]e for 
each separate experiment for the determination of EC50 (i.e., [Ca
2+]e required for 50% of the 
maximal response). The mean EC50 obtained from 4-8 separate transfection experiments were 
used for statistical comparison by using the F-test (3, 8, 18).  
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LEGENDS TO FIGURES 
Figure 1   Schematic representation of AP2S1 gene showing locations of the identified 
variants 
(A) Representation of the genomic organization of the human AP2S1 gene showing the location 
of the identified variants. The AP2S1 gene consists of 5 exons (shaded) with the start (ATG) 
and stop (TGA) codons located in exons 1 and 5, respectively. Untranslated regions are 
represented by open boxes. The Arg (R)15 residue (indicated in grey with a solid line), at which 
the previously reported FHH3-associated mutations of Cys (C), His (H) and Leu (L) have been 
identified (18), is located in exon 2. Two novel AP2σ variants, Phe52Tyr (F52Y) and 
Met117Ile (M117I), identified in the DiscovEHR cohort are located within exons 3 and 5, 
respectively (indicated by a broken line above the exons). The six AP2σ variants (Arg3His 
(A3H), Ala44Thr (A44T), Arg61His (R61H), Thr112Met (T112M), Glu122Gly (E122G), and 
Glu142Lys (E142K)) identified in the ExAc and dbSNP databases are located in exons 2, 3 
and 5, and are shown (by solid lines) below the exons. (B-C) Multiple protein sequence 
alignment of residues comprising (B) the β1-β5 strands and the α1 helix (residues 1-69) and 
(C) the α4 and α5 helices (residues 107-142) of AP2σ-subunit orthologs encoded by AP2S1 
exon 2, 3 and 5. Conserved residues are shaded grey. The WT and variant residues are shown 
in red. The FHH3-associated R15H mutation is shown in blue. The R3, A44, F52, R61, T112, 
M117, E122 and E142 residues are evolutionarily conserved, thereby indicating that they likely 
have important structure-function roles in AP2σ. 
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Figure 2 Structural characterisation of the AP2σ variants encoded by AP2S1 exons 
2 and 3 
(A) Close-up view of the AP2 σ-subunit with the residues having variants within the ExAc 
(Arg3His, Arg61His, Thr112Met, Glu122Gly and Glu142Lys), dbSNP (Ala44Thr) and 
DiscovEHR (Phe52Tyr and Met117Ile) cohorts shown in red. The FHH3 mutations affect the 
Arg15 residue (shown in blue). (B) The AP2σ Arg3 residue is located within the β1 strand that 
lies adjacent to the β2 strand in which the FHH3-associated Arg15 residue is located. Arg3 
forms polar contacts with residues Tyr20, Cys70, Asp72 on the adjacent β2-α1 loop, β4-strand 
and β4-β5 loop, respectively. (C) Mutation of the Arg3 residue to His3 leads to loss of the polar 
contact with Asp72, which may disrupt the stability of the σ-subunit. (D) The Ala44 residue is 
located in the α1-β3 loop, and the Phe52 residue is located distal to this, in the β3 strand. Ala44 
is not predicted to form polar contacts with any neighbouring residues, while Phe52 is predicted 
to form polar contacts with the adjacent Phe55 located in the β4 strand. (E) Mutation of the 
Ala44 and Phe52 residues to Thr44 and Tyr52, respectively, are not predicted to disrupt or 
form new contacts with other AP2σ residues. (F) The Arg61 residue is located in the β4 strand 
that lies within a cluster of β-strands that converge close to the Arg15 AP2σ residue and the 
dileucine motif binding site (black) of cargo proteins, such as the CaSR and other GPCRs. (G) 
Mutation of Arg61 to His61 may affect binding to the cargo protein dileucine recognition motif.        
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Figure 3 Structural characterisation of the AP2σ variants within the AP2σ α4-α5 
helices encoded by AP2S1 exon 5 
(A) Structural model of the α4-helix of the AP2σ subunit (shown in light brown) with the 
adjacent α5-helix of the AP2α subunit (shown in blue). The Thr112 residue forms a polar 
contact with the Tyr108, Lys109 and Glu116 residues on the α4-helix of AP2σ, and the Gln92 
residue on the α5-helix of the AP2α subunit. (B) Mutation of the Thr112 residue to Met112 
leads to loss of the polar contact with Gln92, and therefore may impair AP2σ-AP2α subunit 
interactions. (C) Structural model of the α4-α5 helices of the AP2σ subunit (shown in light 
brown) with the adjacent α12-helix of the AP2α subunit (shown in blue). The Glu122 residue 
is located within the α4-α5 loop, and forms polar contacts with Leu119 of the AP2σ subunit, 
and Ser209 in the α12-helix of the AP2α subunit. (D) Mutation of residue Glu122 to Gly122 
results in loss of the contact with Ser209, and thus the Gly122 variant may impair AP2σ-AP2α 
subunit interactions. (E) Structural model of the α4 and α5 helices of AP2σ (shown in light 
brown) and the AP2α subunit (shown in blue). The Glu142 residue is located at the end of the 
α4-helix of the AP2σ subunit and forms polar contacts with Gly9, Lys56 and Tyr88 of the 
AP2α subunit. (F) Mutation of the Glu142 residue to Lys142 disrupts the polar contact with 
Lys56, and thus the Lys142 variant may impair AP2σ-AP2α subunit interactions. (G) 
Structural model of the α4 helix of AP2σ (shown in light brown) with the Met117 residue 
indicated in red. The Met117 residue forms polar contacts with Val113, Val114 and Arg124. 
(H) Mutation of the Met117 residue to Ile117 is not predicted to alter residue hydrophobicity 
and disrupt these polar contacts.  
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Figure 4 Intracellular calcium responses of cells expressing the AP2σ variants 
(Thr112Met, Met117Ile and Glu142Lys) encoded by AP2S1 exon 5 and located in the 
AP2σ α4-α5 helices   
Ca2+i responses, measured by flow cytometry, to changes in [Ca
2+]e of HEK-CaSR cells 
transfected with wild-type (WT), or (A) Thr112Met, (B) Met117Ile or (C) Glu142Lys AP2σ 
variants (v), or the FHH3-associated Arg15His mutant (m) constructs. The Ca2+i responses to 
changes in [Ca2+]e are expressed as a percentage of the maximum normalised responses and 
shown as the mean±SEM of 4-8 independent transfections. The Thr112Met, Met117Ile and 
Glu142Lys AP2σ variants led to a rightward shift in the concentration-response curve (red 
line), compared to WT. Variant responses were similar to the Arg15His loss-of-function mutant 
(blue line). (D-F) Histograms showing the mean half-maximal concentration (EC50) with 95% 
confidence intervals (CI) and p-values of cells expressing WT (black bar), (D) Thr112Met, (E) 
Met117Ile, or (F) Glu142Lys (red bars) and Arg15His (blue bar) AP2σ proteins. Statistical 
analysis was performed using the F-test. ****p<0.0001, ***p<0.001, compared to WT. 
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Figure 5  Effect of cinacalcet on intracellular calcium responses of cells expressing 
the AP2σ variants Thr112Met, Met117Ile and Glu142Lys 
 
Ca2+i responses, measured by flow cytometry, to changes in [Ca
2+]e of HEK-CaSR cells 
transfected with wild-type (WT) or (A) Thr112Met, (B) Met117Ile or (C) Glu122Gly variants 
(v) AP2σ proteins. The Ca2+i responses to changes in [Ca2+]e are expressed as a percentage of 
the maximum normalised responses and shown as the mean±SEM of 4-8 independent 
transfections. The Thr112Met, Met117Ile and Glu142Gly AP2σ variants led to a rightward 
shift in the concentration-response curve (red line), compared to WT, and the addition of 10nM 
cinacalcet (cin) rectified these rightward shifts of the AP2σ variants (blue line). (D-F) 
Histograms showing the mean half-maximal concentration (EC50) with 95% confidence 
intervals (CI) and p-values of cells expressing WT (black bar), (D) Thr112Met, (E) Met117Ile, 
and (F) Glu142Gly variants treated with vehicle (red bars), or treated with 10nM cinacalcet 
(blue bars) AP2σ proteins. Statistical analysis was performed using the F-test. ****p<0.0001, 
***p<0.001 compared to WT.  
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Table 1  Genotypes and phenotypes of 5 patients with AP2S1 variants from the 
DiscovEHR cohort  
 
aF, female; bserum calcium normal range = 8.30-10.00 mg/dL, which is defined as the mean±2 
standard deviations (SD). Hypercalcaemia is defined as a serum calcium concentration greater 
than 2 SDs above the normal mean, and hypercalcaemia is generally considered to be mild, 
moderate or severe for serum calcium concentrations that are >10.00 mg/dL but <12.00 mg/dL, 
between 12.01 and 14.00 mg/dL, and >14.01 mg/dL, respectively (40). The serum calcium 
concentrations are adjusted or ‘corrected’ to a reference (usually the mean for the normal 
population) albumin concentration, because ~50% of total serum calcium is bound to albumin, 
and thus variations in serum albumin concentration can affect total serum calcium 
concentrations (40). The formula used to derive the total serum calcium concentration adjusted 
for albumin is: adjusted total serum calcium concentration = measured total serum calcium + 
[0.8 x (4.0 – measured total serum albumin concentrations)] (40); cthe initial serum calcium 
value obtained from ambulatory patients in the outpatient department is shown; dserum albumin 
Nucleotide  
Change 
Predicted  
change 
Sexa Age  
(years) 
Total serum calcium 
adjusted for albumin 
(mg/dL)b,c 
Co-existing clinical 
conditions 
c.44G>A Arg15His F 72 10.06 Polycystic kidney 
disease, 
hypothyroidism, 
hypertension, diabetes 
mellitus type 2, 
vitamin D deficiency, 
osteoporosis 
c.44G>A Arg15His F 68 10.08 Multiple sclerosis, 
ita i   eficie c , 
osteoporosis, obesity 
 
 
 
c.44G>A Arg15His F 73 9.80 Pituitary tumour, 
asthma 
c.155G>A Phe52Tyr F 53 9.56 Obesity, vitamin D 
deficiency, 
hypothyroidism c.350G>T Met117Ile F 34 10.10d e- 
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is not available for this patient, and the uncorrected total serum calcium concentration is shown; 
e-, clinical details not available. 
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ABBREVIATIONS 
AP2, adaptor-related protein complex 2; Ca2+e, extracellular calcium; Ca
2+
i, intracellular 
calcium; CaSR, calcium-sensing receptor; dbSNP, database of single nucleotide 
polymorphisms - National Center for Biotechnology Information (NCBI); EC50, mean half-
maximal concentration; ExAc, exome aggregation consortium; FHH, familial hypocalciuric 
hypercalcaemia; Gα11, G-protein alpha-11 subunit; GPCR, G-protein coupled receptor; HBSS, 
Hank’s buffered saline solution; HEK293, human embryonic kidney 293 cells; OMIM, online 
mendelian inheritance in man; PTH, parathyroid hormone; RFP, red fluorescent protein; SEM, 
standard error of the mean; SIFT, sorting tolerant from intolerant; WT, wild-type 
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